Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
6.38
Dollar change
+0.02
Percentage change
0.31
%
IndexRUT P/E- EPS (ttm)-1.12 Insider Own45.45% Shs Outstand49.13M Perf Week-6.59%
Market Cap317.47M Forward P/E- EPS next Y-0.83 Insider Trans-11.46% Shs Float27.14M Perf Month16.85%
Income-54.75M PEG- EPS next Q-0.30 Inst Own32.07% Short Float4.31% Perf Quarter24.12%
Sales81.50M P/S3.90 EPS this Y9.12% Inst Trans-3.38% Short Ratio7.79 Perf Half Y89.88%
Book/sh2.20 P/B2.90 EPS next Y20.28% ROA-31.09% Short Interest1.17M Perf Year-20.75%
Cash/sh2.56 P/C2.49 EPS next 5Y- ROE-42.84% 52W Range1.04 - 9.31 Perf YTD23.64%
Dividend Est.- P/FCF- EPS past 5Y-30.17% ROI-38.10% 52W High-31.45% Beta2.72
Dividend TTM- Quick Ratio12.42 Sales past 5Y72.98% Gross Margin85.73% 52W Low513.46% ATR (14)0.40
Dividend Ex-Date- Current Ratio13.01 EPS Y/Y TTM32.87% Oper. Margin-66.79% RSI (14)51.67 Volatility4.31% 7.16%
Employees214 Debt/Eq0.32 Sales Y/Y TTM8.27% Profit Margin-67.18% Recom2.67 Target Price6.10
Option/ShortYes / Yes LT Debt/Eq0.32 EPS Q/Q6.78% Payout- Rel Volume1.36 Prev Close6.36
Sales Surprise4.72% EPS Surprise-19.57% Sales Q/Q2.34% EarningsMay 02 AMC Avg Volume150.31K Price6.38
SMA20-1.22% SMA507.86% SMA20043.06% Trades Volume205,061 Change0.31%
Date Action Analyst Rating Change Price Target Change
Sep-12-23Downgrade William Blair Outperform → Mkt Perform
Sep-12-23Downgrade Piper Sandler Overweight → Neutral $15 → $5.50
Sep-12-23Downgrade BofA Securities Neutral → Underperform $10 → $4.50
Aug-24-23Downgrade Morgan Stanley Overweight → Equal-Weight $12 → $8.40
Jul-10-23Downgrade Citigroup Buy → Neutral $15 → $9
Jan-06-23Upgrade Stifel Hold → Buy $10 → $15
Oct-04-22Initiated Needham Hold
Jul-26-22Initiated Stifel Hold $10
Feb-03-22Initiated William Blair Outperform
Jan-07-22Upgrade Morgan Stanley Equal-Weight → Overweight $36 → $27
Jun-10-24 04:05PM
May-28-24 04:05PM
08:30AM
May-07-24 04:05PM
May-06-24 10:02AM
01:37PM Loading…
May-03-24 01:37PM
01:04PM
May-02-24 09:55PM
06:20PM
04:05PM
Apr-30-24 11:02AM
Apr-29-24 03:55PM
01:59PM
11:21AM
10:51AM
08:05AM Loading…
08:05AM
Apr-18-24 04:05PM
Apr-10-24 04:05PM
Apr-02-24 04:05PM
Mar-26-24 04:05PM
Mar-08-24 02:53PM
09:16AM
Mar-07-24 10:35PM
09:53PM
05:50PM
04:05PM
Feb-22-24 04:05PM
Feb-21-24 10:25AM
Feb-14-24 04:05PM
Jan-23-24 04:05PM
05:25PM Loading…
Jan-14-24 05:25PM
Jan-08-24 04:05PM
Dec-28-23 09:15AM
Dec-18-23 04:05PM
Dec-08-23 08:05AM
Nov-13-23 03:40PM
Nov-12-23 09:40AM
Nov-07-23 04:05PM
Oct-26-23 05:30PM
Oct-24-23 04:05PM
Oct-19-23 04:05PM
Oct-12-23 04:05PM
Oct-03-23 08:30AM
Sep-12-23 09:53AM
02:55AM
Sep-11-23 04:06PM
04:05PM
Aug-30-23 04:05PM
Aug-03-23 06:35PM
04:05PM
Jul-24-23 09:55AM
Jul-20-23 04:05PM
08:30AM
Jul-17-23 12:00PM
Jun-21-23 08:30AM
Jun-09-23 04:05PM
May-23-23 08:30AM
May-09-23 09:55AM
May-06-23 11:30AM
May-04-23 06:45PM
04:05PM
May-01-23 04:05PM
Apr-26-23 04:05PM
Apr-20-23 04:05PM
Apr-19-23 01:57PM
Apr-13-23 04:05PM
Apr-11-23 05:22AM
Apr-03-23 04:05PM
Mar-30-23 08:00AM
Mar-23-23 11:25AM
Mar-14-23 11:22AM
Mar-13-23 05:25PM
04:05PM
Mar-09-23 08:30AM
Feb-23-23 04:05PM
Feb-22-23 04:05PM
Feb-14-23 07:10AM
Jan-26-23 08:30AM
Jan-09-23 04:20PM
01:15PM
Jan-04-23 10:00AM
Dec-29-22 09:10AM
Dec-13-22 01:09PM
Dec-08-22 08:30AM
Nov-22-22 08:30AM
Nov-16-22 05:21AM
Nov-10-22 05:35PM
04:05PM
Nov-03-22 10:00AM
08:30AM
Oct-20-22 05:20PM
Oct-14-22 10:51AM
Oct-04-22 03:38PM
Sep-29-22 08:30AM
Sep-28-22 08:30AM
Sep-16-22 08:00AM
Sep-13-22 03:01AM
Sep-02-22 08:00AM
Aug-25-22 04:05PM
Aug-23-22 08:03AM
Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bauerlein AlisonChief Financial OfficerMay 17 '24Sale5.4213,06670,870413,182May 20 08:56 PM
Badawi PaulPresident and CEOApr 03 '24Sale5.0812,57163,8485,750,729Apr 04 07:25 PM
Bauerlein AlisonChief Financial OfficerApr 03 '24Sale5.0810,12351,415426,248Apr 04 07:19 PM
HAYDEN JEREMY B.Chief Legal OfficerApr 03 '24Sale5.084,89324,852168,620Apr 04 07:26 PM
Park Sam BoongChief Operating OfficerApr 03 '24Sale5.083,41417,340261,754Apr 04 07:24 PM
Badawi DavidChief Technology OfficerApr 03 '24Sale5.083,12815,8871,762,776Apr 04 07:24 PM
Badawi PaulPresident and CEOJan 17 '24Sale5.1615,91782,1955,319,539Jan 19 04:49 PM
Park Sam BoongChief Operating OfficerJan 17 '24Sale5.165,44328,108100,735Jan 19 04:28 PM
HAYDEN JEREMY B.Chief Legal OfficerJan 17 '24Sale5.164,53823,43410,318Jan 19 04:39 PM
Badawi DavidChief Technology OfficerJan 17 '24Sale5.163,41417,6301,642,157Jan 19 04:43 PM
D1 Capital Partners L.P.10% OwnerDec 27 '23Sale5.862,852,03616,712,9313,000,000Dec 29 08:30 PM
Encrantz StaffanDirectorNov 30 '23Buy3.46140,777486,6381,012,150Dec 01 07:39 PM
Encrantz StaffanDirectorNov 29 '23Buy3.503,22311,280871,373Dec 01 07:39 PM
Encrantz StaffanDirectorNov 28 '23Buy3.46253,669877,137868,150Nov 28 08:32 PM
Encrantz StaffanDirectorNov 27 '23Buy3.31246,331815,947614,481Nov 28 08:32 PM
Badawi DavidChief Technology OfficerNov 24 '23Option Exercise0.11150,00016,5001,631,196Nov 28 08:16 PM
Encrantz StaffanDirectorNov 24 '23Buy3.0921,85567,427368,150Nov 28 08:32 PM
Encrantz StaffanDirectorNov 22 '23Buy2.5041,085102,708346,295Nov 22 06:19 PM
Encrantz StaffanDirectorNov 21 '23Buy2.4868,477169,535305,210Nov 22 06:19 PM
Encrantz StaffanDirectorNov 20 '23Buy2.2579,234178,189236,733Nov 22 06:19 PM
Encrantz StaffanDirectorNov 17 '23Buy2.19126,664277,293157,499Nov 20 09:45 PM
Encrantz StaffanDirectorNov 16 '23Buy2.0033967830,835Nov 20 09:45 PM
Encrantz StaffanDirectorNov 14 '23Buy2.003,4626,91430,496Nov 16 05:44 PM
Park Sam BoongChief Operating OfficerSep 14 '23Option Exercise1.9637,66873,82989,092Sep 15 06:33 PM